A prospective, randomized, single blind, parallel, active controlled, multicentre, non-inferiority, phase III clinical study to evaluate the immunogenicity and safety of single-dose and multi-dose vials of Measles Mumps and Rubella vaccine (Live) (Freeze-dried) of M/s Cadila Healthcare Limited compared to Measles Mumps and Rubella vaccine (Live) (Freeze-dried) of M/s Serum Institute of India Limited in healthy paediatric subjects aged 15-18 months

Trial Profile

A prospective, randomized, single blind, parallel, active controlled, multicentre, non-inferiority, phase III clinical study to evaluate the immunogenicity and safety of single-dose and multi-dose vials of Measles Mumps and Rubella vaccine (Live) (Freeze-dried) of M/s Cadila Healthcare Limited compared to Measles Mumps and Rubella vaccine (Live) (Freeze-dried) of M/s Serum Institute of India Limited in healthy paediatric subjects aged 15-18 months

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Measles mumps and rubella virus vaccine (Primary)
  • Indications Measles; Mumps; Rubella
  • Focus Pharmacodynamics; Registrational
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 17 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top